Viracta Therapeutics to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

Viracta Therapeutics, a precision oncology firm focused on virus-associated cancers, will present at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. EDT. A live webcast of the presentation can be accessed on their Investors page, with an archive available for 30 days. Viracta's key product, an oral combination therapy called Nana-val, is being evaluated in pivotal trials for treating relapsed/refractory Epstein-Barr virus-positive lymphomas and related cancers.

SAN DIEGO, June 1, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 1:30 p.m. EDT.

A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 30 days.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1), as well as a multinational Phase 1b/2 trial for the treatment of EBV⁺ recurrent or metastatic nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-jefferies-healthcare-conference-301559561.html

SOURCE Viracta Therapeutics, Inc.

FAQ

What is Viracta Therapeutics scheduled to present at the Jefferies Healthcare Conference?

Viracta Therapeutics will present at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. EDT.

How can I watch Viracta's presentation at the Jefferies Healthcare Conference?

A live webcast of Viracta's presentation will be available on their Investors section under 'Events and Webcasts'.

What is Nana-val and its significance for Viracta Therapeutics?

Nana-val is Viracta's lead product candidate, an oral combination therapy currently in trials for treating virus-associated malignancies, including relapsed/refractory Epstein-Barr virus-positive lymphoma.

Where can I find more information about Viracta Therapeutics?

More information about Viracta Therapeutics can be found on their official website at www.viracta.com.

What types of cancers does Viracta target?

Viracta Therapeutics targets virus-associated malignancies, focusing on cancers related to Epstein-Barr virus.